Zymeworks Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports corporate governance changes. The report date is June 26, 2023, with the filing signed and board appointment announcement dated June 29, 2023. The director changes became effective June 30, 2023.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other financial performance metrics.
Material Changes
- Carlos Campoy was appointed as a Class I director effective June 30, 2023, with a term expiring at the 2025 annual meeting.
- Dr. Natalie Sacks resigned from the Board and from the nominating and corporate governance and research and development committees, effective June 30, 2023. The filing states that her resignation was not due to disagreement with the Company.
- Mr. Campoy was appointed to the audit committee and the nominating and corporate governance committee, replacing Susan Mahony on the nominating and corporate governance committee. Ms. Mahony remains a director.
- Dr. Kelvin Neu was appointed chair of the research and development committee.
- Mr. Campoy will receive the standard non-employee director compensation package, including an initial option to purchase 50,000 shares of common stock, and will enter into the Company’s standard director and executive officer indemnification agreement.
Committee Composition
| Committee | Members |
|---|---|
| Audit | Lota Zoth, Chair; Troy M. Cox; Carlos Campoy |
| Compensation | Hollings C. Renton, Chair; Susan Mahony; Lota Zoth |
| Nominating and Corporate Governance | Kenneth Hillan, Chair; Troy M. Cox; Carlos Campoy |
| Research and Development | Kelvin Neu, Chair; Kenneth Hillan |
Guidance, Risks, and Unusual Items
No financial guidance, operating outlook, material contingencies, or risk updates are provided. The principal unusual items are the Board resignation, appointment of a new director, committee reassignments, and the planned 50,000-share initial stock option grant.
Investor Verification Items
- Verify the effective date of the Board changes and the apparent distinction between the June 26 earliest event date and the June 29 filing and announcement dates.
- Review the standard non-employee director compensation plan for the terms, vesting, exercise price, and accounting impact of Mr. Campoy’s 50,000-share option.
- Confirm the updated committee memberships and applicable director independence and financial-expertise qualifications in subsequent filings.
- Review Exhibit 99.1 for additional biographical information regarding Mr. Campoy.